As of September 30, 2026, aTyr Pharma, Inc. carries a market capitalization of 30.44M, placing it among publicly traded companies globally. Its enterprise value stands at -7.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 30.44M |
| Enterprise Value | -7.58M |
aTyr Pharma, Inc.'s next confirmed earnings release is scheduled for March 18, 2027.
| Earnings Date | 3/18/2027 |
As of September 30, 2026, aTyr Pharma, Inc. has 2.51M shares outstanding.
| Shares Outstanding | 2.51M |
These figures are as of September 30, 2026.
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | -0.68 |
| P/OCF Ratio | -0.68 |
As of September 30, 2026, aTyr Pharma, Inc. maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.05 |
| Quick Ratio | 3.00 |
| Debt / Equity | 32.31 |
| Debt / EBITDA | -0.20 |
Over the twelve months ended September 30, 2026, aTyr Pharma, Inc. posted a negative return on equity (ROE) of -93.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.07, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -93.37 |
| Return on Assets (ROA) | -64.07 |
| Employee Count | 58.00 |
As of the close on November 16, 2026, aTyr Pharma, Inc.'s stock has declined approximately 82.61% over the past 52 weeks. The 50-day moving average sits at 10.03, while the 200-day moving average is 22.92.
| 52-Week Price Change | -82.61% |
| 50-Day Moving Average | 10.03 |
| 200-Day Moving Average | 22.92 |
Over the twelve months ended September 30, 2026, aTyr Pharma, Inc. generated - - in revenue and converted that into -53.32M in net income, yielding earnings per share of -21.74. EBITDA reached -54.31M, while operating income came in at -55.90M.
| Operating Income | -55.90M |
| Pretax Income | -53.32M |
| Net Income | -53.32M |
| EBITDA | -54.31M |
| EBIT | -55.90M |
| Earnings Per Share (EPS) | -21.74 |
As of September 30, 2026, aTyr Pharma, Inc. holds 48.75M in cash and equivalents against 10.92M in total debt, resulting in a net debt position of -13.14M. Total book value stands at 33.98M, with working capital of 33.69M providing operational flexibility.
| Cash & Cash Equivalents | 48.75M |
| Total Debt | 10.92M |
| Net Debt | -13.14M |
| Equity (Book Value) | 33.98M |
| Book Value Per Share | 13.53 |
| Working Capital | 33.69M |
aTyr Pharma, Inc. produced -43.57M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -287,000.00 in capital expenditures, free cash flow totaled -43.86M - equivalent to -17.89 per share.
| Operating Cash Flow | -43.57M |
| Capital Expenditures | -287,000.00 |
| Free Cash Flow | -43.86M |
| FCF Per Share | -17.89 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -147.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.22, meaning aTyr Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -1.22 |
| FCF Yield | -147.57 |
aTyr Pharma, Inc.'s most recent stock split took place on October 29, 2026 with a 40:1 split ratio.
| Last Split Date | 10/29/2026 |
| Split Ratio | 40:1 |
As of September 30, 2026, aTyr Pharma, Inc. has an Altman Z-Score of -16.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.82 |